ALB and acute kidney injury: In subgroup patients with cisplatin use, the incidence of AKI was comparable among patients treated with ETV, TDF and TAF (p = 0.898, Figure 2E), whereas in subgroup patients with serum albumin <3.7 g/dL, the TAF group had a significantly lower incidence of AKI than the ETV group (13.7% vs. 32.8%, p = 0.004, Figure 2F).